Zelluna Achieves Manufacturing Milestone for First-in-Class MAGE-A4 TCR-NK Cell Therapy
核心洞察
Zelluna (搜索) successfully completed the first GMP batch of ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy for solid tumours (搜索).
The company's proprietary manufacturing process can generate hundreds of doses from a single run, offering scalable production and cost advantages.
Zelluna (搜索) remains on track to file a Clinical Trial Application by year-end 2025, with initial clinical data expected mid-2026.
Zelluna (搜索) has successfully manufactured and quality control tested the first Good Manufacturing Practice (GMP) batch of ZI-MA4-1, marking a critical milestone for the world's first MAGE-A4-targeting T Cell Receptor-based Natural Killer (TCR-NK) cell therapy. The Oslo-based biotechnology company announced on December 12, 2025, that this material is intended for use in its upcoming first-in-human clinical trial.
Manufacturing Process Delivers Scale and Efficiency
The GMP batch was produced using Zelluna (搜索)'s proprietary manufacturing process, which was finalized and locked in April 2025. The process is designed to deliver high-quality TCR-NK products with the ability to generate hundreds of doses from a single manufacturing run, offering both broad patient access and cost-of-goods advantages.
"Having our first GMP batch in storage and ready for our first clinical trial fills us with hope and excitement as we move closer to bringing our TCR-NK therapies to patients," said Emilie Gauthy, Head of CMC at Zelluna (搜索). "This successful GMP run, backed by our robust development data, strengthens our confidence in delivering safe, potent, and consistent therapies at a scale capable of meeting patient's needs."
Novel Approach to Solid Tumour Treatment
ZI-MA4-1 represents a first-in-class approach that harnesses both the innate cancer (搜索)-killing properties of NK cells and the precision targeting of affinity-enhanced TCRs. The therapy is designed to overcome key challenges facing current cell therapies in solid tumours (搜索), including tumour heterogeneity and antigen loss, while offering an anticipated favourable safety profile and broad patient access.
The allogeneic "off-the-shelf" design eliminates the need for patient-specific manufacturing, potentially enabling faster treatment delivery and broader accessibility compared to autologous cell therapies.
Clinical Timeline and Regulatory Path
Zelluna (搜索) remains on track to submit a Clinical Trial Application (CTA) for ZI-MA4-1 in the second half of 2025, with initial clinical data expected mid-2026. CEO Namir Hassan emphasized the significance of this manufacturing achievement as the final operational step before clinical entry.
"Together with our compelling preclinical data showing ZI-MA4-1's potent and selective activity in solid tumour models, this milestone underscores the strength of our science, our process, and our team," Hassan stated. "We believe ZI-MA4-1 is a highly differentiated therapy with the potential to redefine what is possible for patients with solid tumours (搜索)."
The successful GMP batch production represents a crucial validation of Zelluna (搜索)'s manufacturing capabilities and positions the company to advance its lead program into human testing, potentially offering a new treatment paradigm for patients with solid tumours (搜索) expressing the MAGE-A4 antigen.